

# Kenneth J Pienta

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4377177/publications.pdf>

Version: 2024-02-01

570  
papers

63,713  
citations

1027

117  
h-index

1166

236  
g-index

600  
all docs

600  
docs citations

600  
times ranked

64453  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cancer cell foraging to explain bone-specific metastatic progression. <i>Bone</i> , 2022, 158, 115788.	1.4	8
2	The European Association of Urology Biochemical Recurrence Risk Groups Predict Findings on PSMA PET in Patients with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy. <i>Journal of Nuclear Medicine</i> , 2022, 63, 248-252.	2.8	13
3	Advancements in the identification of EV derived mRNA biomarkers for liquid biopsy of clear cell renal cell carcinomas. <i>Urology</i> , 2022, 160, 87-93.	0.5	7
4	Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomics. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 713-719.	2.0	17
5	Characterization of Cellular and Acellular Analytes from Pre-Cystectomy Liquid Biopsies in Patients Newly Diagnosed with Primary Bladder Cancer. <i>Cancers</i> , 2022, 14, 758.	1.7	10
6	Piflufolostat F 18-PET/CT in prostate cancer patients: An analysis of OSPREY (Cohorts A and B) standardized uptake value (SUV) results stratified by PSA and gleason score.. <i>Journal of Clinical Oncology</i> , 2022, 40, 35-35.	0.8	0
7	Transcriptomic discriminators of response to apalutamide in patients with prostate cancer (PC) on active surveillance (AS).. <i>Journal of Clinical Oncology</i> , 2022, 40, 267-267.	0.8	0
8	High SUVs Have More Robust Repeatability in Patients with Metastatic Prostate Cancer: Results from a Prospective Test-Retest Cohort Imaged with <sup>18</sup> F-DCFPyL. <i>Molecular Imaging</i> , 2022, 2022, 7056983.	0.7	6
9	Extracellular Vesicle Uptake Assay & Confocal Microscope Imaging Analysis. <i>Journal of Visualized Experiments</i> , 2022, , .	0.2	0
10	Robots as models of evolving systems. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2120019119.	3.3	10
11	<sup>177</sup> Lu-PSMA radioligand therapy effectiveness in metastatic castration-resistant prostate cancer: An updated systematic review and meta-analysis. <i>Prostate</i> , 2022, 82, 826-835.	1.2	20
12	Predictors of <sup>18</sup> F-DCFPyL PET/CT Positivity in Patients with Biochemical Recurrence of Prostate Cancer After Local Therapy. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1184-1190.	2.8	12
13	Interplay between Cell Death and Cell Proliferation Reveals New Strategies for Cancer Therapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4723.	1.8	27
14	Interim analysis of companion, prospective, phase II, clinical trials assessing the efficacy and safety of multi-modal total eradication therapy in men with synchronous oligometastatic prostate cancer. <i>Medical Oncology</i> , 2022, 39, 63.	1.2	6
15	Abstract B022: The polyan euploid transition as a hedge against failures in resistance acquisition. <i>Cancer Research</i> , 2022, 82, B022-B022.	0.4	0
16	Abstract IA017: The polyan euploid cancer cell state as a mediator of therapeutic resistance. <i>Cancer Research</i> , 2022, 82, IA017-IA017.	0.4	0
17	Abstract A001: Modeling cancer's ecological and evolutionary dynamics. <i>Cancer Research</i> , 2022, 82, A001-A001.	0.4	0
18	Abstract B015: Eco-evolutionary dynamics of poly-aneuploid cancer cells: A life history model. <i>Cancer Research</i> , 2022, 82, B015-B015.	0.4	0

#	ARTICLE	IF	CITATIONS
19	Piflufolostat F-18 ( <sup>18</sup> F-DCFPyL) for PSMA PET imaging in prostate cancer. Expert Review of Anticancer Therapy, 2022, 22, 681-694.	1.1	9
20	Piflufolostat F 18-PET/CT in patients with prostate cancer: An analysis of OSPREY (cohorts A and B) standardized uptake value (SUV) results stratified by PSA and Gleason score.. Journal of Clinical Oncology, 2022, 40, 5024-5024.	0.8	1
21	Prostate-specific membrane antigen PET response associates with radiographic progression-free survival following stereotactic ablative radiation therapy in oligometastatic castration-sensitive prostate cancer.. Journal of Clinical Oncology, 2022, 40, 5011-5011.	0.8	2
22	Targeting B7-H3 in prostate cancer: Phase 2 trial in localized prostate cancer using the anti-B7-H3 antibody enoblituzumab, with biomarker correlatives.. Journal of Clinical Oncology, 2022, 40, 5015-5015.	0.8	3
23	Neuropilin-2 regulates androgen-receptor transcriptional activity in advanced prostate cancer. Oncogene, 2022, 41, 3747-3760.	2.6	6
24	Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer. European Urology Oncology, 2021, 4, 447-455.	2.6	52
25	Patterns of Recurrence and Modes of Progression After Metastasis-Directed Therapy in Oligometastatic Castration-Sensitive Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2021, 109, 387-395.	0.4	19
26	CT-based assessment of body composition following neoadjuvant chemohormonal therapy in patients with castration-sensitive oligometastatic prostate cancer. Prostate, 2021, 81, 127-134.	1.2	9
27	A novel method for detection of exfoliated prostate cancer cells in urine by RNA in situ hybridization. Prostate Cancer and Prostatic Diseases, 2021, 24, 220-232.	2.0	3
28	Circulating Tumor Cell and Circulating Tumor DNA Assays Reveal Complementary Information for Patients with Metastatic Urothelial Cancer. European Urology Oncology, 2021, 4, 310-314.	2.6	28
29	The role of liquid biopsies in prostate cancer management. Lab on A Chip, 2021, 21, 3263-3288.	3.1	9
30	Detection of Early Progression with <sup>18</sup> F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy. Journal of Nuclear Medicine, 2021, 62, 1270-1273.	2.8	6
31	Cancer recurrence and lethality are enabled by enhanced survival and reversible cell cycle arrest of polyaneploid cells. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	61
32	The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited. European Urology, 2021, 80, 632-640.	0.9	61
33	High-Throughput Simultaneous mRNA Profiling Using nCounter Technology Demonstrates That Extracellular Vesicles Contain Different mRNA Transcripts Than Their Parental Prostate Cancer Cells. Analytical Chemistry, 2021, 93, 3717-3725.	3.2	15
34	Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen-Targeted <sup>18</sup> F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide. Journal of Nuclear Medicine, 2021, 62, 1430-1437.	2.8	24
35	Understanding the tumor-immune microenvironment in prostate cancer. Current Opinion in Oncology, 2021, 33, 231-237.	1.1	5
36	Identifying key questions in the ecology and evolution of cancer. Evolutionary Applications, 2021, 14, 877-892.	1.5	58

#	ARTICLE	IF	CITATIONS
37	A prospective phase II/III study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A subanalysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging.. Journal of Clinical Oncology, 2021, 39, 32-32.	0.8	2
38	High KIF1C1 expression is associated with poor prognosis in prostate cancer. Medical Oncology, 2021, 38, 47.	1.2	14
39	Characterization of extracellular vesicles and synthetic nanoparticles with four orthogonal single-particle analysis platforms. Journal of Extracellular Vesicles, 2021, 10, e12079.	5.5	97
40	Effect of Point-Spread Function Reconstruction for Indeterminate PSMA-RADS-3A Lesions on PSMA-Targeted PET Imaging of Men with Prostate Cancer. Diagnostics, 2021, 11, 665.	1.3	6
41	Characterization of tumor-associated macrophages in prostate cancer transgenic mouse models. Prostate, 2021, 81, 629-647.	1.2	10
42	ROS-induced cell cycle arrest as a mechanism of resistance in polyan euploid cancer cells (PACCs). Progress in Biophysics and Molecular Biology, 2021, 165, 3-7.	1.4	36
43	CD38 in Advanced Prostate Cancers. European Urology, 2021, 79, 736-746.	0.9	21
44	Peripheral androgen blockade in men with castrate-sensitive biochemical recurrent prostate cancer. Medical Oncology, 2021, 38, 80.	1.2	2
45	Quantitative and Qualitative Analysis of Blood-based Liquid Biopsies to Inform Clinical Decision-making in Prostate Cancer. European Urology, 2021, 79, 762-771.	0.9	47
46	Polyaneuploid Cancer Cell Dormancy: Lessons From Evolutionary Phyla. Frontiers in Ecology and Evolution, 2021, 9, .	1.1	6
47	Reply by Authors. Journal of Urology, 2021, 206, 61-61.	0.2	2
48	Defining candidate mRNA and protein EV biomarkers to discriminate ccRCC and pRCC from non-malignant renal cells in vitro. Medical Oncology, 2021, 38, 105.	1.2	5
49	A Systematic Review and Meta-analysis of the Effectiveness and Toxicities of Lutetium-177-labeled Prostate-specific Membrane Antigen-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer. European Urology, 2021, 80, 82-94.	0.9	53
50	A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with <sup>18</sup> F-DCFPyL in Prostate Cancer Patients (OSPREY). Journal of Urology, 2021, 206, 52-61.	0.2	180
51	Lipid droplet evolution gives insight into polyan euploid cancer cell lipid droplet functions. Medical Oncology, 2021, 38, 133.	1.2	11
52	Supraphysiologic Testosterone Induces Ferroptosis and Activates Immune Pathways through Nucleophagy in Prostate Cancer. Cancer Research, 2021, 81, 5948-5962.	0.4	30
53	It doesn't always pay to be fit: success landscapes. Journal of Biological Physics, 2021, 47, 387-400.	0.7	3
54	Prostate cancer research in the 21st century; report from the 2021 Coffey-Holden prostate cancer academy meeting. Prostate, 2021, .	1.2	2

#	ARTICLE	IF	CITATIONS
55	Measurement of PET Quantitative Bias In Vivo. <i>Journal of Nuclear Medicine</i> , 2021, 62, 732-737.	2.8	3
56	Twelve unanswered questions in cancer inspired by the life and work of Leland Chung: "if this is true, what does it imply"?. <i>American Journal of Clinical and Experimental Urology</i> , 2021, 9, 254-260.	0.4	0
57	Cell-morphodynamic phenotype classification with application to cancer metastasis using cell magnetorotation and machine-learning. <i>PLoS ONE</i> , 2021, 16, e0259462.	1.1	5
58	720â€¦CUE-102 selectively activates and expands WT1-specific T cells for the treatment of patients with WT1+ malignancies. , 2021, 9, A749-A749.		0
59	Semiquantitative Parameters in PSMA-Targeted PET Imaging with [18F]DCFPyL: Inpatient and Interpatient Variability of Normal Organ Uptake. <i>Molecular Imaging and Biology</i> , 2020, 22, 181-189.	1.3	14
60	Prospective Evaluation of PSMA-Targeted <sup>18</sup> F-DCFPyL PET/CT in Men with Biochemical Failure After Radical Prostatectomy for Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 58-61.	2.8	61
61	Semiquantitative Parameters in PSMA-Targeted PET Imaging with [18F]DCFPyL: Impact of Tumor Burden on Normal Organ Uptake. <i>Molecular Imaging and Biology</i> , 2020, 22, 190-197.	1.3	27
62	Re: Identification and Characterization of Circulating Tumor Cells in Men Who Have Undergone Prostatectomy of Clinically Localized, High Risk Prostate Cancer. <i>European Urology</i> , 2020, 77, 285.	0.9	0
63	Prospective Comparison of PET Imaging with PSMA-Targeted <sup>18</sup> F-DCFPyL Versus Na <sup>18</sup> F for Bone Lesion Detection in Patients with Metastatic Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 183-188.	2.8	27
64	Letter to the Editor re: "Semiquantitative Parameters in PSMA-Targeted PET Imaging with [18F]DCFPyL: Impact of Tumor Burden on Normal Organ Uptake". <i>Molecular Imaging and Biology</i> , 2020, 22, 19-21.	1.3	0
65	Online Prostate-Specific Membrane Antigen and Positron Emission Tomography "Guided Radiation Therapy for Oligometastatic Prostate Cancer. <i>Advances in Radiation Oncology</i> , 2020, 5, 260-268.	0.6	13
66	Prostate cancer research: The next generation; report from the 2019 Coffeyâ€¦Holden Prostate Cancer Academy Meeting. <i>Prostate</i> , 2020, 80, 113-132.	1.2	25
67	Analysis of the Circulating Tumor Cell Capture Ability of a Slit Filter-Based Method in Comparison to a Selection-Free Method in Multiple Cancer Types. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9031.	1.8	4
68	Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting. <i>Prostate</i> , 2020, 80, 1273-1296.	1.2	16
69	Modes of Failure Following Metastasis Directed Therapy in Patients with Oligometastatic Hormone Sensitive Prostate Cancer: A Multi-institutional Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, e869-e870.	0.4	0
70	Prospective evaluation of 68Ga-PSMA-11 PET/CT in Chinese men with biochemical recurrence after radical prostatectomy for prostate cancer: relationships between location of recurrence, time after prostatectomy, and serum PSA level. <i>Medical Oncology</i> , 2020, 37, 89.	1.2	5
71	Game Theory Cancer Models of Cancer Cell-Stromal Cell Dynamics using Interacting Particle Systems. <i>Biophysical Reviews and Letters</i> , 2020, 15, 171-193.	0.9	3
72	The issues with tissues: the wide range of cell fate separation enables the evolution of multicellularity and cancer. <i>Medical Oncology</i> , 2020, 37, 62.	1.2	5

#	ARTICLE	IF	CITATIONS
73	A phase II randomized trial of Radium-223 dichloride and SABR Versus SABR for oligometastatic prostate cancer (RAVENS). BMC Cancer, 2020, 20, 492.	1.1	16
74	An in vitro tumor swamp model of heterogeneous cellular and chemotherapeutic landscapes. Lab on a Chip, 2020, 20, 2453-2464.	3.1	8
75	Extracellular vesicle isolation from human renal cancer tissue. Medical Oncology, 2020, 37, 28.	1.2	23
76	Perspectives in Oncology: a new article type for Medical Oncology. Medical Oncology, 2020, 37, 21.	1.2	0
77	Cancer Cells and M2 Macrophages: Cooperative Invasive Ecosystem Engineers. Cancer Control, 2020, 27, 107327482091105.	0.7	16
78	Wnt Signaling Drives Prostate Cancer Bone Metastatic Tropism and Invasion. Translational Oncology, 2020, 13, 100747.	1.7	36
79	The combination of size-based separation and selection-free technology provides higher circulating tumour cells detection sensitivity than either method alone in patients with metastatic prostate cancer. BJU International, 2020, 126, 191-201.	1.3	7
80	Polyaneuploid cancer cells promote evolvability, generating lethal cancer. Evolutionary Applications, 2020, 13, 1626-1634.	1.5	54
81	CUE-101, a Novel E7-pHLA-IL2-Fc Fusion Protein, Enhances Tumor Antigen-Specific T-Cell Activation for the Treatment of HPV16-Driven Malignancies. Clinical Cancer Research, 2020, 26, 1953-1964.	3.2	35
82	Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer. JAMA Oncology, 2020, 6, 650.	3.4	696
83	NF- $\kappa$ B p50-deficient immature myeloid cell (p50-IMC) adoptive transfer slows the growth of murine prostate and pancreatic ductal carcinoma. , 2020, 8, e000244.		7
84	Convergent Evolution, Evolving Evolvability, and the Origins of Lethal Cancer. Molecular Cancer Research, 2020, 18, 801-810.	1.5	48
85	Comprehensive evaluation of methods for small extracellular vesicles separation from human plasma, urine and cell culture medium. Journal of Extracellular Vesicles, 2020, 10, e12044.	5.5	97
86	PD38-05: CLINICAL UTILITY OF PREOPERATIVE PSMA-TARGETED <sup>18</sup> F-DCFPYL PET/CT IN MEN WITH HIGH-RISK PROSTATE CANCER: DIAGNOSTIC PERFORMANCE COMPARISONS WITH PELVIC CT OR MRI IN THE OSPREY PROSPECTIVE, MULTI-CENTER TRIAL. Journal of Urology, 2020, 203, .	0.2	1
87	Prostate Specific Antigen and Prostate Specific Antigen Doubling Time Predict Findings on 18 F-DCFPyL Positron Emission Tomography/Computerized Tomography in Patients with Biochemically Recurrent Prostate Cancer. Journal of Urology, 2020, 204, 496-502.	0.2	12
88	A prospective phase II/III multicenter study of PSMA-targeted 18F-DCFPyL PET/CT imaging in patients with prostate cancer (OSPREY): A sub-analysis of regional and distant metastases detection rates at initial staging by 18F-DCFPyL PET/CT.. Journal of Clinical Oncology, 2020, 38, 9-9.	0.8	10
89	Feasibility of digital pathology of circulating tumor cells with morphologic analysis in localized bladder cancer.. Journal of Clinical Oncology, 2020, 38, 525-525.	0.8	0
90	A phase II randomized trial of Radium-223 dichloride and SABR versus SABR for oligometastatic prostate cancer (RAVENS).. Journal of Clinical Oncology, 2020, 38, TPS5586-TPS5586.	0.8	1

#	ARTICLE	IF	CITATIONS
91	Abstract 6493: Optimized methods for studies of extracellular vesicles in kidney cancer. , 2020, , .		0
92	Abstract 342: Profiling mRNAs of parental prostate cancer cells with different phenotypes and their daughter extracellular vesicles using the NanoString low RNA input nCounter assay. , 2020, , .		0
93	Abstract 5365: Profiling circulating tumor cell RNA from a large blood screening volume: A pilot study using diagnostic leukapheresis followed by the NanoString low RNA input nCounter assay. , 2020, , .		0
94	A phase II randomized trial of Observation versus stereotactic ablative Radiatlon for OLigometastatic prostate CancEr (ORIOLE).. Journal of Clinical Oncology, 2020, 38, 116-116.	0.8	1
95	Abstract B68: NF- $\kappa$ B p50-deficient immature myeloid cell (p50-IMC) adoptive transfer slows the growth of murine prostate and pancreatic ductal carcinoma. , 2020, , .		0
96	PD51-03â€¦DIGITAL PATHOLOGY OF CIRCULATING TUMOR CELLS WITH MORPHOLOGIC ANALYSIS IS FEASIBLE IN LOCALIZED BLADDER CANCER. Journal of Urology, 2020, 203, e1084.	0.2	0
97	Immune profiling of the bone marrow microenvironment in patients with high-risk localized prostate cancer. Oncotarget, 2020, 11, 4253-4265.	0.8	1
98	Can the interplay between androgen signaling and PSMA expression be leveraged for theranostic applications?. Translational Andrology and Urology, 2019, 8, S263-S264.	0.6	6
99	Polyploid giant cancer cells: Unrecognized actuators of tumorigenesis, metastasis, and resistance. Prostate, 2019, 79, 1489-1497.	1.2	116
100	Detection and isolation of disseminated tumor cells in bone marrow of patients with clinically localized prostate cancer. Prostate, 2019, 79, 1715-1727.	1.2	18
101	Radiation Therapy in the Definitive Management of Oligometastatic Prostate Cancer: The Johns Hopkins Experience. International Journal of Radiation Oncology Biology Physics, 2019, 105, 948-956.	0.4	37
102	Clinical Outcomes in Oligometastatic Prostate Cancer Following Definitive Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2019, 105, E573-E574.	0.4	0
103	Primary Outcomes of a Phase II Randomized Trial of Observation Versus Stereotactic Ablative Radiatlon for OLigometastatic Prostate CancEr (ORIOLE). International Journal of Radiation Oncology Biology Physics, 2019, 105, 681.	0.4	23
104	Gleason pattern 5 is associated with an increased risk for metastasis following androgen deprivation therapy and radiation: An analysis of RTOG 9202 and 9902. Radiotherapy and Oncology, 2019, 141, 137-143.	0.3	8
105	Primary prostate cancer educates bone stroma through exosomal pyruvate kinase M2 to promote bone metastasis. Journal of Experimental Medicine, 2019, 216, 2883-2899.	4.2	122
106	Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment. Molecular Cancer, 2019, 18, 94.	7.9	237
107	Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer: An Update on Important Pitfalls. Seminars in Nuclear Medicine, 2019, 49, 255-270.	2.5	81
108	Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone. Journal of Clinical Oncology, 2019, 37, 923-931.	0.8	78

#	ARTICLE	IF	CITATIONS
109	Novel Structured Reporting Systems for Theranostic Radiotracers. <i>Journal of Nuclear Medicine</i> , 2019, 60, 577-584.	2.8	24
110	Imaging and Characterization of Macrophage Distribution in Mouse Models of Human Prostate Cancer. <i>Molecular Imaging and Biology</i> , 2019, 21, 1054-1063.	1.3	10
111	PSMA-targeted [ <sup>18</sup> F]DCFPyL PET/CT-avid lesions in a patient with prostate cancer: Clinical decision-making informed by the PSMA-RADS interpretive framework. <i>Urology Case Reports</i> , 2019, 23, 72-74.	0.1	5
112	Recent advances in extracellular vesicle research for urological cancers: From technology to application. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019, 1871, 342-360.	3.3	16
113	Computational Modeling of the Crosstalk Between Macrophage Polarization and Tumor Cell Plasticity in the Tumor Microenvironment. <i>Frontiers in Oncology</i> , 2019, 9, 10.	1.3	55
114	The role of heterogeneous environment and docetaxel gradient in the emergence of polyploid, mesenchymal and resistant prostate cancer cells. <i>Clinical and Experimental Metastasis</i> , 2019, 36, 97-108.	1.7	51
115	Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation. <i>Journal of Visualized Experiments</i> , 2019, , .	0.2	2
116	Mannose Receptorâ€“positive Macrophage Infiltration Correlates with Prostate Cancer Onset and Metastatic Castration-resistant Disease. <i>European Urology Oncology</i> , 2019, 2, 429-436.	2.6	46
117	Hereditary Spherocytosis Presenting as Diffuse Bone Marrow Activation and Splenomegaly on PSMA-Targeted <sup>18</sup> F-DCFPyL PET/CT. <i>Clinical Nuclear Medicine</i> , 2019, 44, e313-e314.	0.7	3
118	Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment. <i>World Journal of Urology</i> , 2019, 37, 2623-2629.	1.2	21
119	Follow-up of Lesions with Equivocal Radiotracer Uptake on PSMA-Targeted PET in Patients with Prostate Cancer: Predictive Values of the PSMA-RADS-3A and PSMA-RADS-3B Categories. <i>Journal of Nuclear Medicine</i> , 2019, 60, 511-516.	2.8	29
120	Optimization of prostate cancer cell detection using multiplex tyramide signal amplification. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 4804-4812.	1.2	14
121	Prostate-specific markers to identify rare prostate cancer cells in liquid biopsies. <i>Nature Reviews Urology</i> , 2019, 16, 7-22.	1.9	39
122	Cooperation among cancer cells: applying game theory to cancer. <i>Nature Reviews Cancer</i> , 2019, 19, 110-117.	12.8	118
123	Tumor cell heterogeneity and resistance; report from the 2018 Coffeyâ€“Holden Prostate Cancer Academy Meeting. <i>Prostate</i> , 2019, 79, 244-258.	1.2	13
124	Metastatic prostate cancer remains incurable, why?. <i>Asian Journal of Urology</i> , 2019, 6, 26-41.	0.5	103
125	AXL Is a Putative Tumor Suppressor and Dormancy Regulator in Prostate Cancer. <i>Molecular Cancer Research</i> , 2019, 17, 356-369.	1.5	36
126	Diagnostic performance of <sup>18</sup> F-DCFPyL in the OSPREY Trial: A prospective phase 2/3 multicenter study of <sup>18</sup> F-DCFPyL PET/CT imaging in patients (Pts) with known or suspected metastatic prostate cancer (mPC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 5012-5012.	0.8	3



#	ARTICLE	IF	CITATIONS
127	Uptake of prostate-specific membrane antigen-targeted 18F-DCFPyL in avascular necrosis of the femoral head. <i>World Journal of Nuclear Medicine</i> , 2019, 18, 416-419.	0.3	3
128	Vas deferens infiltration by prostate cancer on prostate-specific membrane antigen-targeted 18F-DCFPyL positron emission tomography/computed tomography: A unique visual pattern. <i>World Journal of Nuclear Medicine</i> , 2019, 18, 424-427.	0.3	2
129	PD60-10â€¦A PROSPECTIVE PHASE 2/3 MULTI-CENTER STUDY OF 18 F-DCFPYL PET/CT IMAGING IN PATIENTS WITH PROSTATE CANCER â€œ EXAMINATION OF DIAGNOSTIC ACCURACY (OSPREY). <i>Journal of Urology</i> , 2019, 201, .	0.2	0
130	MPO5-02â€¦CTC AND CTDNA ASSAYS REVEAL COMPLIMENTARY INFORMATION FOR METASTATIC UROTHELIAL CANCER PATIENTS. <i>Journal of Urology</i> , 2019, 201, .	0.2	0
131	Abstract 4582: Mannose receptor positive macrophage infiltrate correlates with prostate cancer onset and metastatic castration-resistant disease. , 2019, , .		1
132	Abstract 4556: Targeting the TAM receptors on prostate cancer tumor-associated macrophages. , 2019, , .		0
133	Abstract 1383: Isolating circulating tumor cells from a large screening blood volume: A pilot study using diagnostic leukapheresis. , 2019, , .		0
134	Abstract 2360: Targeting IL-4R alpha on tumor-associated macrophages as a therapeutic strategy for prostate cancer. , 2019, , .		0
135	Abstract 1078: An immunosuppressive signature in bone marrow as a potential biomarker for recurrence of metastatic prostate cancer after prostatectomy. , 2019, , .		0
136	Abstract 1358: Tumor-derived extracellular vesicles as kidney cancer biomarkers. , 2019, , .		0
137	Abstract 3774: Elevated cancer evolution dynamics: Emergence of polyploid cancer cells in response to multimodal therapy as an adaptive response on both individual and collective levels. , 2019, , .		0
138	Abstract 4597: Bladder cancer patients experience circulating tumor cell number surge during intramedullary nailing procedures intended for treating pathological fractures. , 2019, , .		0
139	PBOV1 as a potential biomarker for more advanced prostate cancer based on protein and digital histomorphometric analysis. <i>Prostate</i> , 2018, 78, 547-559.	1.2	13
140	A Voice From the Past: Rediscovering the Virchow Node With Prostate-specific Membrane Antigen-targeted 18 F-DCFPyL Positron Emission Tomography Imaging. <i>Urology</i> , 2018, 117, 18-21.	0.5	16
141	Targeting the tumour stroma to improve cancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 366-381.	12.5	719
142	CXCL12 <sup>Î²</sup> Promotes Metastatic Castration-Resistant Prostate Cancer by Inducing Cancer Stem Cell and Neuroendocrine Phenotypes. <i>Cancer Research</i> , 2018, 78, 2026-2039.	0.4	46
143	Characterization of Urothelial Cancer Circulating Tumor Cells with a Novel Selection-Free Method. <i>Urology</i> , 2018, 115, 82-86.	0.5	16
144	Integrin alpha V beta 3 targeted dendrimerâ€¦rapamycin conjugate reduces fibroblastâ€¦mediated prostate tumor progression and metastasis. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 8074-8083.	1.2	17

#	ARTICLE	IF	CITATIONS
145	Cancer dormancy and criticality from a game theory perspective. <i>Cancer Convergence</i> , 2018, 2, 1.	8.0	6
146	Diagnosing small bowel carcinoid tumor in a patient with oligometastatic prostate cancer imaged with PSMA-Targeted [ <sup>18</sup> F]DCFPyL PET/CT: Value of the PSMA-RADS-3D Designation. <i>Urology Case Reports</i> , 2018, 17, 22-25.	0.1	7
147	Analogous detection of circulating tumor cells using the AccuCyte <sup>®</sup> CyteFinder <sup>®</sup> system and ISET system in patients with locally advanced and metastatic prostate cancer. <i>Prostate</i> , 2018, 78, 300-307.	1.2	19
148	Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group. <i>Prostate</i> , 2018, 78, 775-789.	1.2	35
149	Prostate Cancer Disseminated Tumor Cells are Rarely Detected in the Bone Marrow of Patients with Localized Disease Undergoing Radical Prostatectomy across Multiple Rare Cell Detection Platforms. <i>Journal of Urology</i> , 2018, 199, 1494-1501.	0.2	21
150	SSTR-RADS Version 1.0 as a Reporting System for SSTR PET Imaging and Selection of Potential PRRT Candidates: A Proposed Standardization Framework. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1085-1091.	2.8	58
151	Low-Level Endogenous PSMA Expression in Nonprostatic Tumor Xenografts Is Sufficient for In Vivo Tumor Targeting and Imaging. <i>Journal of Nuclear Medicine</i> , 2018, 59, 486-493.	2.8	27
152	Proposal for a Structured Reporting System for Prostate-Specific Membrane Antigen-Targeted PET Imaging: PSMA-RADS Version 1.0. <i>Journal of Nuclear Medicine</i> , 2018, 59, 479-485.	2.8	122
153	Re: Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer. <i>European Urology</i> , 2018, 73, 478.	0.9	1
154	Complete biochemical response after stereotactic ablative radiotherapy of an isolated prostate cancer pelvic soft tissue recurrence detected by <sup>18</sup> F-DCFPyL PET/CT. <i>Urology Case Reports</i> , 2018, 16, 86-88.	0.1	4
155	Patient-Paired Sample Congruence Between 2 Commercial Liquid Biopsy Tests. <i>JAMA Oncology</i> , 2018, 4, 868.	3.4	160
156	PSMA-RADS Version 1.0: A Step Towards Standardizing the Interpretation and Reporting of PSMA-targeted PET Imaging Studies. <i>European Urology</i> , 2018, 73, 485-487.	0.9	108
157	Prostate Specific Membrane Antigen Targeted <sup>18</sup> F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study. <i>Journal of Urology</i> , 2018, 199, 126-132.	0.2	86
158	Epigenetic control of macrophage polarization: implications for targeting tumor-associated macrophages. <i>Oncotarget</i> , 2018, 9, 20908-20927.	0.8	82
159	Uptake of Prostate-Specific Membrane Antigen-Targeted <sup>18</sup> F-DCFPyL in Cerebral Radionecrosis. <i>Clinical Nuclear Medicine</i> , 2018, 43, e419-e421.	0.7	24
160	3D Cell Nuclear Morphology: Microscopy Imaging Dataset and Voxel-Based Morphometry Classification Results. , 2018, , .		14
161	SABR Produces Systemic Adaptive Immune Responses in Castration-Sensitive Oligometastatic Prostate Cancer Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, S24-S25.	0.4	1
162	Interim Results of a Randomized Trial of Observation Versus SABR for Castration-Sensitive Oligometastatic Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, e134-e135.	0.4	2

#	ARTICLE	IF	CITATIONS
163	Cancer Foraging Ecology: Diet Choice, Patch Use, and Habitat Selection of Cancer Cells. <i>Current Pathobiology Reports</i> , 2018, 6, 209-218.	1.6	15
164	Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on <sup>18</sup> F-DCFPyL PET/CT Imaging. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1857-1864.	2.8	43
165	3D Shape Modeling for Cell Nuclear Morphological Analysis and Classification. <i>Scientific Reports</i> , 2018, 8, 13658.	1.6	22
166	Cancer as a Social Dysfunction—Why Cancer Research Needs New Thinking. <i>Molecular Cancer Research</i> , 2018, 16, 1346-1347.	1.5	11
167	Compositional differences in gastrointestinal microbiota in prostate cancer patients treated with androgen axis-targeted therapies. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 539-548.	2.0	99
168	Regarding the Congruence Between 2 Circulating Tumor DNA Sequencing Assays—Reply. <i>JAMA Oncology</i> , 2018, 4, 1431.	3.4	4
169	Molecular imaging reporting and data systems (MI-RADS): a generalizable framework for targeted radiotracers with theranostic implications. <i>Annals of Nuclear Medicine</i> , 2018, 32, 512-522.	1.2	37
170	Optimization of Immunofluorescent Detection of Bone Marrow Disseminated Tumor Cells. <i>Biological Procedures Online</i> , 2018, 20, 13.	1.4	14
171	Absence of myeloid Klf4 reduces prostate cancer growth with pro-atherosclerotic activation of tumor myeloid cells and infiltration of CD8 T cells. <i>PLoS ONE</i> , 2018, 13, e0191188.	1.1	13
172	O-GlcNAcylation is required for mutant KRAS-induced lung tumorigenesis. <i>Journal of Clinical Investigation</i> , 2018, 128, 4924-4937.	3.9	51
173	A prospective phase 2/3 multicenter study of <sup>18</sup> F-DCFPyL PET/CT imaging in patients with prostate cancer: Examination of diagnostic accuracy (OSPREY).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS5092-TPS5092.	0.8	4
174	Results of a phase II trial of neoadjuvant abiraterone + prednisone+ enzalutamide + leuprolide (APEL) versus enzalutamide + leuprolide (EL) for patients with high-risk localized prostate cancer (PC) undergoing radical prostatectomy (RP).. <i>Journal of Clinical Oncology</i> , 2018, 36, 79-79.	0.8	3
175	Symmetry and symmetry breaking in cancer: a foundational approach to the cancer problem. <i>Oncotarget</i> , 2018, 9, 11429-11440.	0.8	21
176	Ten unanswered questions in cancer: "If this is true, what does it imply"?. <i>American Journal of Clinical and Experimental Urology</i> , 2018, 6, 26-31.	0.4	2
177	A surface tension magnetophoretic device for rare cell isolation and characterization. <i>Medical Oncology</i> , 2017, 34, 22.	1.2	5
178	Biomanufacturing Seamless Tubular and Hollow Collagen Scaffolds with Unique Design Features and Biomechanical Properties. <i>Advanced Healthcare Materials</i> , 2017, 6, 1601136.	3.9	16
179	Revisiting Seed and Soil: Examining the Primary Tumor and Cancer Cell Foraging in Metastasis. <i>Molecular Cancer Research</i> , 2017, 15, 361-370.	1.5	79
180	Nucleolin Staining May Aid in the Identification of Circulating Prostate Cancer Cells. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e477-e481.	0.9	14

#	ARTICLE	IF	CITATIONS
181	<p>TWIST1-WDR5-<i>Hottip</i> Regulates <i>Hoxa9</i> Chromatin to Facilitate Prostate Cancer Metastasis. <i>Cancer Research</i>, 2017, 77, 3181-3193.</p>	0.4	102
182	<p>The prostate metastasis suppressor gene NDRG1 differentially regulates cell motility and invasion. <i>Molecular Oncology</i>, 2017, 11, 655-669.</p>	2.1	35
183	<p>The Identification of Macrophage-enriched Glycoproteins Using Glycoproteomics. <i>Molecular and Cellular Proteomics</i>, 2017, 16, 1029-1037.</p>	2.5	14
184	<p>RB Loss Promotes Prostate Cancer Metastasis. <i>Cancer Research</i>, 2017, 77, 982-995.</p>	0.4	67
185	<p>Semiquantitative Parameters in PSMA-Targeted PET Imaging with <sup>18</sup>F-DCFPyL: Variability in Normal-Organ Uptake. <i>Journal of Nuclear Medicine</i>, 2017, 58, 942-946.</p>	2.8	38
186	<p>Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling. <i>Cancer Cell</i>, 2017, 32, 474-489.e6.</p>	7.7	483
187	<p>An Unusual Case of Penile Prostate Cancer Uncovered by Multiparametric MRI and PSMA-Targeted 18F-DCFPyL PET/CT. <i>Clinical Nuclear Medicine</i>, 2017, 42, e441-e443.</p>	0.7	1
188	<p>Epithelial and mesenchymal prostate cancer cell population dynamics on a complex drug landscape. <i>Convergent Science Physical Oncology</i>, 2017, 3, 045001.</p>	2.6	12
189	<p>Classifying the evolutionary and ecological features of neoplasms. <i>Nature Reviews Cancer</i>, 2017, 17, 605-619.</p>	12.8	303
190	<p>Tenascin-C and Integrin <math>\alpha 9</math> Mediate Interactions of Prostate Cancer with the Bone Microenvironment. <i>Cancer Research</i>, 2017, 77, 5977-5988.</p>	0.4	59
191	<p>Beyond the androgen receptor II: New approaches to understanding and treating metastatic prostate cancer; Report from the 2017 Coffey-Holden Prostate Cancer Academy Meeting. <i>Prostate</i>, 2017, 77, 1478-1488.</p>	1.2	7
192	<p>Oligometastatic prostate cancer. <i>Current Opinion in Urology</i>, 2017, 27, 533-541.</p>	0.9	30
193	<p>Uptake of the prostate-specific membrane antigen-targeted PET radiotracer 18F-DCFPyL in elastofibroma dorsi. <i>Nuclear Medicine Communications</i>, 2017, 38, 795-798.</p>	0.5	5
194	<p>Defining the clinical utility of PSMA-targeted PET imaging of prostate cancer. <i>BJU International</i>, 2017, 120, 160-161.</p>	1.3	3
195	<p>Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i>, 2017, 44, 2117-2136.</p>	3.3	234
196	<p>Selection-free method reveals phenotypic diversity among prostate cancer circulating tumour cells. <i>BJU International</i>, 2017, 120, E4.</p>	1.3	2
197	<p>Prostate Cancer Local Recurrence Detected With Both 18 F-Fluciclovine and PSMA-targeted 18 F-DCFPyL PET/CT. <i>Urology</i>, 2017, 107, e9-e10.</p>	0.5	8
198	<p>Identifying global expression patterns and key regulators in epithelial to mesenchymal transition through multi-study integration. <i>BMC Cancer</i>, 2017, 17, 447.</p>	1.1	26

#	ARTICLE	IF	CITATIONS
199	A phase II randomized trial of Observation versus stereotactic ablative Radiation for Oligometastatic prostate Cancer (ORIOLE). BMC Cancer, 2017, 17, 453.	1.1	83
200	Correlation of PSMA-Targeted 18F-DCFPyL PET/CT Findings With Immunohistochemical and Genomic Data in a Patient With Metastatic Neuroendocrine Prostate Cancer. Clinical Genitourinary Cancer, 2017, 15, e65-e68.	0.9	61
201	Prediction of the Pathologic Gleason Score to Inform a Personalized Management Program for Prostate Cancer. European Urology, 2017, 72, 135-141.	0.9	20
202	A Bayesian Hierarchical Model for Prediction of Latent Health States from Multiple Data Sources with Application to Active Surveillance of Prostate Cancer. Biometrics, 2017, 73, 625-634.	0.8	23
203	Risk prediction tool for grade reclassification in men with favourable risk prostate cancer on active surveillance. BJU International, 2017, 120, 25-31.	1.3	29
204	Beyond Seed and Soil: Understanding and Targeting Metastatic Prostate Cancer; Report From the 2016 Coffey-Holden Prostate Cancer Academy Meeting. Prostate, 2017, 77, 123-144.	1.2	6
205	Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. Nature Reviews Urology, 2017, 14, 15-25.	1.9	210
206	Circulating tumour cells as biomarkers of prostate, bladder, and kidney cancer. Nature Reviews Urology, 2017, 14, 90-97.	1.9	78
207	Patterns of uptake of prostate-specific membrane antigen (PSMA)-targeted 18F-DCFPyL in peripheral ganglia. Annals of Nuclear Medicine, 2017, 31, 696-702.	1.2	34
208	Cell surface Thomsen-Friedenreich proteome profiling of metastatic prostate cancer cells reveals potential link with cancer stem cell-like phenotype. Oncotarget, 2017, 8, 98598-98608.	0.8	16
209	Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide. Journal of Clinical Oncology, 2017, 35, 2149-2156.	0.8	371
210	Apoptosis-induced CXCL5 accelerates inflammation and growth of prostate tumor metastases in bone. Journal of Clinical Investigation, 2017, 128, 248-266.	3.9	103
211	Stereotactic ablative radiation therapy for the treatment of oligometastatic prostate cancer.. Journal of Clinical Oncology, 2017, 35, 5020-5020.	0.8	2
212	A phase II randomized trial of observation versus stereotactic ablative radiation for oligometastatic prostate cancer (ORIOLE).. Journal of Clinical Oncology, 2017, 35, TPS5094-TPS5094.	0.8	0
213	A secondary analysis of PSA response in NRG Oncology/RTOG 9902: A phase III trial of adjuvant chemotherapy with androgen suppression and radiation for high-risk prostate cancer (CaP).. Journal of Clinical Oncology, 2017, 35, 5078-5078.	0.8	0
214	Stability of the hybrid epithelial/mesenchymal phenotype. Oncotarget, 2016, 7, 27067-27084.	0.8	367
215	A phased strategy to differentiate human CD14 <sup>+</sup> monocytes into classically and alternatively activated macrophages and dendritic cells. BioTechniques, 2016, 61, 33-41.	0.8	92
216	A Novel Approach for Performing Bone Marrow Aspiration at the Time of Radical Prostatectomy. Urology Case Reports, 2016, 6, 45-46.	0.1	0

#	ARTICLE	IF	CITATIONS
217	Role of biobanking in urology: a review. <i>BJU International</i> , 2016, 118, 864-868.	1.3	6
218	Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E6457-E6466.	3.3	44
219	DNMT1 Regulates Epithelial-Mesenchymal Transition and Cancer Stem Cells, Which Promotes Prostate Cancer Metastasis. <i>Neoplasia</i> , 2016, 18, 553-566.	2.3	103
220	Positive Feedback Loops Between Inflammatory, Bone and Cancer Cells During Metastatic Niche Construction. <i>Advances in Experimental Medicine and Biology</i> , 2016, 936, 137-148.	0.8	3
221	Murine Hind Limb Long Bone Dissection and Bone Marrow Isolation. <i>Journal of Visualized Experiments</i> , 2016, , .	0.2	166
222	Murine Prostate Micro-dissection and Surgical Castration. <i>Journal of Visualized Experiments</i> , 2016, , .	0.2	13
223	A phase 2 trial of salvage radiation and concurrent weekly docetaxel after a rising prostate-specific antigen level after radical prostatectomy. <i>Advances in Radiation Oncology</i> , 2016, 1, 59-66.	0.6	6
224	Multidisciplinary intervention of early, lethal metastatic prostate cancer: Report from the 2015 Coffey-Holden Prostate Cancer Academy Meeting. <i>Prostate</i> , 2016, 76, 125-139.	1.2	17
225	PSMA-Based Detection of Prostate Cancer Bone Lesions With 18F-DCFPyL PET/CT: A Sensitive Alternative to 99mTc-MDP Bone Scan and Na18F PET/CT?. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e115-e118.	0.9	50
226	Polyclonal breast cancer metastases arise from collective dissemination of keratin 14-expressing tumor cell clusters. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E854-63.	3.3	576
227	Disseminated tumor cells and dormancy in prostate cancer metastasis. <i>Current Opinion in Biotechnology</i> , 2016, 40, 9-15.	3.3	59
228	Ecological paradigms to understand the dynamics of metastasis. <i>Cancer Letters</i> , 2016, 380, 237-242.	3.2	44
229	AR-V7 and efficacy of abiraterone (Abi) and enzalutamide (Enza) in castration-resistant prostate cancer (CRPC): Expanded analysis of the Johns Hopkins cohort.. <i>Journal of Clinical Oncology</i> , 2016, 34, 5012-5012.	0.8	16
230	Development of an Automated and Sensitive Microfluidic Device for Capturing and Characterizing Circulating Tumor Cells (CTCs) from Clinical Blood Samples. <i>PLoS ONE</i> , 2016, 11, e0147400.	1.1	82
231	Technical challenges in the isolation and analysis of circulating tumor cells. <i>Oncotarget</i> , 2016, 7, 62754-62766.	0.8	84
232	A simple selection-free method for detecting disseminated tumor cells (DTCs) in murine bone marrow. <i>Oncotarget</i> , 2016, 7, 69794-69803.	0.8	5
233	Contemporary treatment patterns and short-term outcomes in men with very high-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 103-103.	0.8	0
234	Development of an automated and sensitive microfluidic device for circulating tumor cell (CTC) analysis and single cell capturing.. <i>Journal of Clinical Oncology</i> , 2016, 34, e23031-e23031.	0.8	0

#	ARTICLE	IF	CITATIONS
235	Computer extracted nuclear features from Feulgen and H&E images to predict biochemical recurrence in prostate cancer patients following radical prostatectomy.. Journal of Clinical Oncology, 2016, 34, 5067-5067.	0.8	0
236	Computer extracted features on H&E images to improve biochemical recurrence prediction of Kattan nomogram for prostate cancer patients following radical prostatectomy: Preliminary findings.. Journal of Clinical Oncology, 2016, 34, 11556-11556.	0.8	0
237	Integrated Multimodal Imaging of Dynamic Bone-Tumor Alterations Associated with Metastatic Prostate Cancer. PLoS ONE, 2015, 10, e0123877.	1.1	9
238	Ecology meets cancer biology: The cancer swamp promotes the lethal cancer phenotype. Oncotarget, 2015, 6, 9669-9678.	0.8	72
239	The biology and treatment of oligometastatic cancer. Oncotarget, 2015, 6, 8491-8524.	0.8	243
240	Glycolysis is the primary bioenergetic pathway for cell motility and cytoskeletal remodeling in human prostate and breast cancer cells. Oncotarget, 2015, 6, 130-143.	0.8	151
241	Integrative Clinical Genomics of Advanced Prostate Cancer. Cell, 2015, 161, 1215-1228.	13.5	2,660
242	Aerobic glycolysis, motility, and cytoskeletal remodeling. Cell Cycle, 2015, 14, 169-170.	1.3	9
243	Oligometastatic Prostate Cancer to the Navicular Bone: Case Report. Urology Case Reports, 2015, 3, 59-62.	0.1	2
244	Beyond immune checkpoint blockade: New approaches to targeting host-tumor interactions in prostate cancer: Report from the 2014 Coffey-Holden prostate cancer Academy meeting. Prostate, 2015, 75, 337-347.	1.2	12
245	A Phase 3 Trial of 2 Years of Androgen Suppression and Radiation Therapy With or Without Adjuvant Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902. International Journal of Radiation Oncology Biology Physics. 2015, 93, 294-302.	0.4	60
246	Drug discovery in prostate cancer mouse models. Expert Opinion on Drug Discovery, 2015, 10, 1011-1024.	2.5	14
247	Alternative CD44 splicing identifies epithelial prostate cancer cells from the mesenchymal counterparts. Medical Oncology, 2015, 32, 159.	1.2	21
248	A multi-targeted approach to treating bone metastases. , 2015, , 647-655.		1
249	Epithelial-mesenchymal transition in prostate cancer is associated with quantifiable changes in nuclear structure. Prostate, 2015, 75, 218-224.	1.2	16
250	Magnetic Resonanceâ€“invisible Versus Magnetic Resonanceâ€“visible Prostate Cancer in Active Surveillance: A Preliminary Report on Disease Outcomes. Urology, 2015, 85, 147-154.	0.5	50
251	The Presence of Androgen Receptor Elements Regulates ZEB1 Expression in the Absence of Androgen Receptor. Journal of Cellular Biochemistry, 2015, 116, 115-123.	1.2	14
252	Tumor Repression of VCaP Xenografts by a Pyrrole-Imidazole Polyamide. PLoS ONE, 2015, 10, e0143161.	1.1	24

#	ARTICLE	IF	CITATIONS
253	OVOL guides the epithelial-hybrid-mesenchymal transition. <i>Oncotarget</i> , 2015, 6, 15436-15448.	0.8	121
254	Coupling the modules of EMT and stemness: A tunable "stemness window"™ model. <i>Oncotarget</i> , 2015, 6, 25161-25174.	0.8	157
255	Bone marrow macrophages support prostate cancer growth in bone. <i>Oncotarget</i> , 2015, 6, 35782-35796.	0.8	62
256	Therapy decisions for the symptomatic patient with metastatic castration-resistant prostate cancer. <i>Asian Journal of Andrology</i> , 2015, 17, 936.	0.8	1
257	Targeting Efferocytic M2 Monocytes and Macrophages Offers Therapeutic Promise in Prostate Cancer Skeletal Metastasis. <i>FASEB Journal</i> , 2015, 29, LB457.	0.2	0
258	Classification of current anticancer immunotherapies. <i>Oncotarget</i> , 2014, 5, 12472-12508.	0.8	395
259	Axl as a mediator of cellular growth and survival. <i>Oncotarget</i> , 2014, 5, 8818-8852.	0.8	150
260	Endothelial integrin $\alpha_5\beta_1$ stabilizes carbohydrate-mediated tumor/endothelial cell adhesion and induces macromolecular signaling complex formation at the endothelial cell membrane. <i>Oncotarget</i> , 2014, 5, 1382-1389.	0.8	28
261	Genetic Ablation of Metadherin Inhibits Autochthonous Prostate Cancer Progression and Metastasis. <i>Cancer Research</i> , 2014, 74, 5336-5347.	0.4	37
262	TAM macrophages promote growth and metastasis within the cancer ecosystem. <i>Oncolmmunology</i> , 2014, 3, e941734.	2.1	30
263	Frequent discordance between <i>ERG</i> gene rearrangement and ERG protein expression in a rapid autopsy cohort of patients with lethal, metastatic, castration-resistant prostate cancer. <i>Prostate</i> , 2014, 74, 1199-1208.	1.2	33
264	Polarization of Prostate Cancer-associated Macrophages Is Induced by Milk Fat Globule-EGF Factor 8 (MFG-E8)-mediated Efferocytosis. <i>Journal of Biological Chemistry</i> , 2014, 289, 24560-24572.	1.6	140
265	Beyond the androgen receptor: New approaches to treating metastatic prostate cancer. Report of the 2013 Prouts Neck Prostate Cancer Meeting. <i>Prostate</i> , 2014, 74, 314-320.	1.2	14
266	Molecular Mechanisms of Prostate Cancer Progression After Castration. <i>Current Clinical Urology</i> , 2014, , 31-41.	0.0	0
267	A multi-targeted approach to treating bone metastases. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 545-553.	2.7	14
268	Cross-Species Regulatory Network Analysis Identifies a Synergistic Interaction between FOXM1 and CENPF that Drives Prostate Cancer Malignancy. <i>Cancer Cell</i> , 2014, 25, 638-651.	7.7	293
269	Niche Inheritance: A Cooperative Pathway to Enhance Cancer Cell Fitness Through Ecosystem Engineering. <i>Journal of Cellular Biochemistry</i> , 2014, 115, 1478-1485.	1.2	45
270	Dynamic Regulation of Rad51 by E2F1 and p53 in Prostate Cancer Cells upon Drug-Induced DNA Damage under Hypoxia. <i>Molecular Pharmacology</i> , 2014, 85, 866-876.	1.0	28



#	ARTICLE	IF	CITATIONS
271	Critical transitions in a game theoretic model of tumour metabolism. <i>Interface Focus</i> , 2014, 4, 20140014.	1.5	52
272	A bioinformatics approach reveals novel interactions of the OVOL transcription factors in the regulation of epithelial to mesenchymal cell reprogramming and cancer progression. <i>BMC Systems Biology</i> , 2014, 8, 29.	3.0	13
273	Response to "Comment on "A method to measure cellular adhesion utilizing a polymer micro-cantilever" [Appl. Phys. Lett. 104, 236103 (2014)]. <i>Applied Physics Letters</i> , 2014, 104, 236104.	1.5	1
274	Circulating fibroblast-like cells in men with metastatic prostate cancer. <i>Prostate</i> , 2013, 73, 176-181.	1.2	50
275	TBK1 Regulates Prostate Cancer Dormancy through mTOR Inhibition. <i>Neoplasia</i> , 2013, 15, 1064-1074.	2.3	97
276	The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. <i>Nature Genetics</i> , 2013, 45, 1392-1398.	9.4	601
277	Identification of Targetable FGFR Gene Fusions in Diverse Cancers. <i>Cancer Discovery</i> , 2013, 3, 636-647.	7.7	614
278	Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. <i>Nature Genetics</i> , 2013, 45, 180-185.	9.4	662
279	Activating ESR1 mutations in hormone-resistant metastatic breast cancer. <i>Nature Genetics</i> , 2013, 45, 1446-1451.	9.4	925
280	Erythropoietin supports the survival of prostate cancer, but not growth and bone metastasis. <i>Journal of Cellular Biochemistry</i> , 2013, 114, 2471-2478.	1.2	11
281	New and Emerging Therapies for Bone Metastases in Genitourinary Cancers. <i>European Urology</i> , 2013, 63, 309-320.	0.9	42
282	Re: Androgen Receptor Splice Variants Mediate Enzalutamide Resistance in Castration-resistant Prostate Cancer Cell Lines. <i>European Urology</i> , 2013, 64, 339-340.	0.9	6
283	Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis. <i>Nature Communications</i> , 2013, 4, 1795.	5.8	342
284	Cancer stem cells and their role in metastasis. , 2013, 138, 285-293.		203
285	Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer. <i>Investigational New Drugs</i> , 2013, 31, 760-768.	1.2	297
286	The Cancer Diaspora: Metastasis beyond the Seed and Soil Hypothesis. <i>Clinical Cancer Research</i> , 2013, 19, 5849-5855.	3.2	95
287	Definition of Molecular Determinants of Prostate Cancer Cell Bone Extravasation. <i>Cancer Research</i> , 2013, 73, 942-952.	0.4	61
288	Prostate cancer originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 20111-20116.	3.3	144

#	ARTICLE	IF	CITATIONS
289	Metastatic castration-resistant prostate cancer reveals inpatient similarity and interpatient heterogeneity of therapeutic kinase targets. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, E4762-9.	3.3	99
290	A method to measure cellular adhesion utilizing a polymer micro-cantilever. <i>Applied Physics Letters</i> , 2013, 103, 123702.	1.5	14
291	GAS6 Receptor Status Is Associated with Dormancy and Bone Metastatic Tumor Formation. <i>PLoS ONE</i> , 2013, 8, e61873.	1.1	109
292	Transcription Factors OVOL1 and OVOL2 Induce the Mesenchymal to Epithelial Transition in Human Cancer. <i>PLoS ONE</i> , 2013, 8, e76773.	1.1	229
293	Circulating microRNA Profiling Identifies a Subset of Metastatic Prostate Cancer Patients with Evidence of Cancer-Associated Hypoxia. <i>PLoS ONE</i> , 2013, 8, e69239.	1.1	147
294	IL-6 induces proliferation in prostate cancer PC3 cells under nutrient-depletion stress through the activation of the JNK pathway and survivin up-regulation. <i>Journal of Cellular Biochemistry</i> , 2012, 113, 1569-1580.	1.2	65
295	Common Structural and Epigenetic Changes in the Genome of Castration-Resistant Prostate Cancer. <i>Cancer Research</i> , 2012, 72, 616-625.	0.4	111
296	Cyclophosphamide Creates a Receptive Microenvironment for Prostate Cancer Skeletal Metastasis. <i>Cancer Research</i> , 2012, 72, 2522-2532.	0.4	67
297	Disseminated Prostate Cancer Cells Can Instruct Hematopoietic Stem and Progenitor Cells to Regulate Bone Phenotype. <i>Molecular Cancer Research</i> , 2012, 10, 282-292.	1.5	41
298	Disrupting the Networks of Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 2801-2808.	3.2	44
299	Role of Transcriptional Corepressor CtBP1 in Prostate Cancer Progression. <i>Neoplasia</i> , 2012, 14, 905-918.	2.3	59
300	Systemic Delivery of Oncolytic Adenoviruses Targeting Transforming Growth Factor- $\beta$ Inhibits Established Bone Metastasis in a Prostate Cancer Mouse Model. <i>Human Gene Therapy</i> , 2012, 23, 871-882.	1.4	67
301	Hypoxia Stabilizes GAS6/Axl Signaling in Metastatic Prostate Cancer. <i>Molecular Cancer Research</i> , 2012, 10, 703-712.	1.5	93
302	The mutational landscape of lethal castration-resistant prostate cancer. <i>Nature</i> , 2012, 487, 239-243.	13.7	2,128
303	Prevalence of Prostate Cancer Metastases after Intravenous Inoculation Provides Clues into the Molecular Basis of Dormancy in the Bone Marrow Microenvironment. <i>Neoplasia</i> , 2012, 14, 429-439.	2.3	51
304	Inhibition of Prostate Cancer Bone Metastasis by Synthetic TF Antigen Mimic/Galectin-3 Inhibitor Lactulose-l-Leucine. <i>Neoplasia</i> , 2012, 14, 65-73.	2.3	79
305	Prostate Cancer and Parasitism of the Bone Hematopoietic Stem Cell Niche. <i>Critical Reviews in Eukaryotic Gene Expression</i> , 2012, 22, 131-148.	0.4	25
306	Role of dutasteride in pre-clinical ETS fusion-positive prostate cancer models. <i>Prostate</i> , 2012, 72, 1542-1549.	1.2	13

#	ARTICLE	IF	CITATIONS
307	384 hanging drop arrays give excellent factors and allow versatile formation of co-culture spheroids. <i>Biotechnology and Bioengineering</i> , 2012, 109, 1293-1304.	1.7	114
308	Micro-ring structures stabilize microdroplets to enable long term spheroid culture in 384 hanging drop array plates. <i>Biomedical Microdevices</i> , 2012, 14, 313-323.	1.4	106
309	Forging the Association for Clinical and Translational Science (ACTS). <i>Clinical and Translational Science</i> , 2012, 5, 117-118.	1.5	1
310	Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium. <i>Investigational New Drugs</i> , 2012, 30, 749-757.	1.2	72
311	The prostate cancer bone marrow niche: more than just "fertile soil". <i>Asian Journal of Andrology</i> , 2012, 14, 423-427.	0.8	50
312	Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. <i>Genome Research</i> , 2011, 21, 47-55.	2.4	148
313	Detection of Somatic Copy Number Alterations in Cancer Using Targeted Exome Capture Sequencing. <i>Neoplasia</i> , 2011, 13, 1019-IN21.	2.3	74
314	Activation of Urokinase Plasminogen Activator and Its Receptor Axis Is Essential for Macrophage Infiltration in a Prostate Cancer Mouse Model. <i>Neoplasia</i> , 2011, 13, 23-30.	2.3	52
315	Therapeutic Targeting of SPINK1-Positive Prostate Cancer. <i>Science Translational Medicine</i> , 2011, 3, 72ra17.	5.8	140
316	Mechanisms of cancer cell metastasis to the bone: a multistep process. <i>Future Oncology</i> , 2011, 7, 1285-1297.	1.1	154
317	Drugs which inhibit osteoclast function suppress tumor growth through calcium reduction in bone. <i>Bone</i> , 2011, 48, 1354-1361.	1.4	16
318	Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets. <i>Cancer Discovery</i> , 2011, 1, 487-495.	7.7	725
319	The Clinical and Translational Science Awards (CTSAs) Are Transforming the Way Academic Medical Institutions Approach Translational Research: The University of Michigan Experience. <i>Clinical and Translational Science</i> , 2011, 4, 233-235.	1.5	3
320	Mechanistic Rationale for Inhibition of Poly(ADP-Ribose) Polymerase in ETS Gene Fusion-Positive Prostate Cancer. <i>Cancer Cell</i> , 2011, 19, 664-678.	7.7	397
321	Chemical transfection of dye-conjugated microRNA precursors for microRNA functional analysis of M2 macrophages. <i>Journal of Cellular Biochemistry</i> , 2011, 113, n/a-n/a.	1.2	4
322	Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study. <i>Science Translational Medicine</i> , 2011, 3, 111ra121.	5.8	531
323	Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium. <i>Investigational New Drugs</i> , 2011, 29, 1432-1440.	1.2	49
324	Homing of Cancer Cells to the Bone. <i>Cancer Microenvironment</i> , 2011, 4, 221-235.	3.1	66

#	ARTICLE	IF	CITATIONS
325	Modeling invasion of metastasizing cancer cells to bone marrow utilizing ecological principles. <i>Theoretical Biology and Medical Modelling</i> , 2011, 8, 36.	2.1	28
326	Inhibitory effects of megakaryocytic cells in prostate cancer skeletal metastasis. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 125-134.	3.1	38
327	Characterization of Bone Metastases from Rapid Autopsies of Prostate Cancer Patients. <i>Clinical Cancer Research</i> , 2011, 17, 3924-3932.	3.2	69
328	Inherited Variants in the Chemokine CCL2 Gene and Prostate Cancer Aggressiveness in a Caucasian Cohort. <i>Clinical Cancer Research</i> , 2011, 17, 1546-1552.	3.2	19
329	Hematopoietic Stem Cell Niche Is a Potential Therapeutic Target for Bone Metastatic Tumors. <i>Clinical Cancer Research</i> , 2011, 17, 5553-5558.	3.2	81
330	Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. <i>Journal of Clinical Investigation</i> , 2011, 121, 1298-1312.	3.9	628
331	Nanoparticle Induced Cell Magneto-Rotation: Monitoring Morphology, Stress and Drug Sensitivity of a Suspended Single Cancer Cell. <i>PLoS ONE</i> , 2011, 6, e28475.	1.1	36
332	The CTSA Mandate: Are We There Yet?. <i>Research and Theory for Nursing Practice</i> , 2010, 24, 64-73.	0.2	5
333	Single cell trapping in larger microwells capable of supporting cell spreading and proliferation. <i>Microfluidics and Nanofluidics</i> , 2010, 8, 263-268.	1.0	90
334	CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression. <i>Cancer and Metastasis Reviews</i> , 2010, 29, 709-722.	2.7	633
335	Successfully Accelerating Translational Research at an Academic Medical Center: The University of Michigan-Coulter Translational Research Partnership Program. <i>Clinical and Translational Science</i> , 2010, 3, 316-318.	1.5	20
336	AT-101 (a novel gossypol acetic acid) enhances the effectiveness of androgen deprivation therapy in the VCaP prostate cancer model. <i>Journal of Cellular Biochemistry</i> , 2010, 110, 1187-1194.	1.2	21
337	Characterization of Phosphoglycerate Kinase-1 Expression of Stromal Cells Derived from Tumor Microenvironment in Prostate Cancer Progression. <i>Cancer Research</i> , 2010, 70, 471-480.	0.4	104
338	Multiple Roles of Chemokine (C-C Motif) Ligand 2 in Promoting Prostate Cancer Growth. <i>Journal of the National Cancer Institute</i> , 2010, 102, 522-528.	3.0	207
339	Targeting Chemokine (C-C motif) Ligand 2 (CCL2) as an Example of Translation of Cancer Molecular Biology to the Clinic. <i>Progress in Molecular Biology and Translational Science</i> , 2010, 95, 31-53.	0.9	79
340	CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. <i>Cytokine and Growth Factor Reviews</i> , 2010, 21, 41-48.	3.2	232
341	GAS6/AXL Axis Regulates Prostate Cancer Invasion, Proliferation, and Survival in the Bone Marrow Niche. <i>Neoplasia</i> , 2010, 12, 116-IN4.	2.3	263
342	Erythropoietin Couples Hematopoiesis with Bone Formation. <i>PLoS ONE</i> , 2010, 5, e10853.	1.1	138

#	ARTICLE	IF	CITATIONS
343	A Multi-targeted Approach to Treating Bone Metastases. , 2010, , 441-448.		0
344	Alpha 1,3 fucosyltransferases are master regulators of prostate cancer cell trafficking. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 19491-19496.	3.3	109
345	Quantitative Analysis of Circulating Tumor Cells as a Survival Predictor in Metastatic Castration-Resistant Prostate Cancer: Missing Parts in a Superb Study. Clinical Cancer Research, 2009, 15, 1504-1505.	3.2	5
346	A Destructive Cascade Mediated by CCL2 Facilitates Prostate Cancer Growth in Bone. Cancer Research, 2009, 69, 1685-1692.	0.4	144
347	CCL2 and Interleukin-6 Promote Survival of Human CD11b+ Peripheral Blood Mononuclear Cells and Induce M2-type Macrophage Polarization. Journal of Biological Chemistry, 2009, 284, 34342-34354.	1.6	474
348	Prostate cancer promotes CD11b positive cells to differentiate into osteoclasts. Journal of Cellular Biochemistry, 2009, 106, 563-569.	1.2	27
349	Synergy between anti-CCL2 and docetaxel as determined by DW-MRI in a metastatic bone cancer model. Journal of Cellular Biochemistry, 2009, 107, 58-64.	1.2	64
350	Tomlins et al. reply. Nature, 2009, 457, E2-E3.	13.7	6
351	<i>FYN</i> is overexpressed in human prostate cancer. BJU International, 2009, 103, 171-177.	1.3	79
352	Phase III Multi-Institutional Trial of Adjuvant Chemotherapy With Paclitaxel, Estramustine, and Oral Etoposide Combined With Long-Term Androgen Suppression Therapy and Radiotherapy Versus Long-Term Androgen Suppression Plus Radiotherapy Alone for High-Risk Prostate Cancer: Preliminary Toxicity Analysis of RTOG 99-02. International Journal of Radiation Oncology Biology Physics, 2009, 73, 672-678.	0.4	59
353	Microfluidic system for formation of PC-3 prostate cancer co-culture spheroids. Biomaterials, 2009, 30, 3020-3027.	5.7	274
354	Treatment-Dependent Androgen Receptor Mutations in Prostate Cancer Exploit Multiple Mechanisms to Evade Therapy. Cancer Research, 2009, 69, 4434-4442.	0.4	190
355	Critical Appraisal of Prostate-specific Antigen in Prostate Cancer Screening: 20 Years Later. Urology, 2009, 73, S11-S20.	0.5	44
356	Regulation of Prostate Cancer Progression by Galectin-3. American Journal of Pathology, 2009, 174, 1515-1523.	1.9	104
357	Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncology, The, 2009, 10, 233-239.	5.1	558
358	The Chemokine CCL2 Increases Prostate Tumor Growth and Bone Metastasis through Macrophage and Osteoclast Recruitment. Neoplasia, 2009, 11, 1235-1242.	2.3	186
359	CCL2 Is a Negative Regulator of AMP-Activated Protein Kinase to Sustain mTOR Complex-1 Activation, Survivin Expression, and Cell Survival in Human Prostate Cancer PC3 Cells. Neoplasia, 2009, 11, 1309-1317.	2.3	46
360	Possible mechanism of CCL2-induced Akt activation in prostate cancer cells. Anticancer Research, 2009, 29, 3109-13.	0.5	13

#	ARTICLE	IF	CITATIONS
361	CD26/dipeptidyl peptidase IV regulates prostate cancer metastasis by degrading SDF-1/CXCL12. <i>Clinical and Experimental Metastasis</i> , 2008, 25, 765-776.	1.7	76
362	The current state of preclinical prostate cancer animal models. <i>Prostate</i> , 2008, 68, 629-639.	1.2	121
363	Dickkopf-1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasis. <i>Prostate</i> , 2008, 68, 1396-1404.	1.2	127
364	Tumor expressed PTHrP facilitates prostate cancer-induced osteoblastic lesions. <i>International Journal of Cancer</i> , 2008, 123, 2267-2278.	2.3	90
365	CCL2 induces prostate cancer transendothelial cell migration via activation of the small GTPase Rac. <i>Journal of Cellular Biochemistry</i> , 2008, 104, 1587-1597.	1.2	46
366	Novel surface expression of reticulocalbin 1 on bone endothelial cells and human prostate cancer cells is regulated by TNF- $\alpha$ . <i>Journal of Cellular Biochemistry</i> , 2008, 104, 2298-2309.	1.2	31
367	Annexin II/Annexin II receptor axis regulates adhesion, migration, homing, and growth of prostate cancer. <i>Journal of Cellular Biochemistry</i> , 2008, 105, 370-380.	1.2	215
368	The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites. <i>Leukemia</i> , 2008, 22, 941-950.	3.3	192
369	Re: RANKL Inhibition Is an Effective Adjuvant for Docetaxel in a Prostate Cancer Bone Metastasis Model. <i>European Urology</i> , 2008, 54, 688.	0.9	1
370	(-)-Gossypol promotes the apoptosis of bladder cancer cells in vitro. <i>Pharmacological Research</i> , 2008, 58, 323-331.	3.1	37
371	A sequence-based survey of the complex structural organization of tumor genomes. <i>Genome Biology</i> , 2008, 9, R59.	13.9	31
372	Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 2192-2202.	1.9	171
373	Ecological Therapy for Cancer: Defining Tumors Using an Ecosystem Paradigm Suggests New Opportunities for Novel Cancer Treatments. <i>Translational Oncology</i> , 2008, 1, 158-164.	1.7	150
374	An In Vivo Mouse Model for Human Prostate Cancer Metastasis. <i>Neoplasia</i> , 2008, 10, 371-IN4.	2.3	74
375	Characterization of TMPRSS2-ETS Gene Aberrations in Androgen-Independent Metastatic Prostate Cancer. <i>Cancer Research</i> , 2008, 68, 3584-3590.	0.4	249
376	Molecularly Targeted Radiosensitization of Human Prostate Cancer by Modulating Inhibitor of Apoptosis. <i>Clinical Cancer Research</i> , 2008, 14, 7701-7710.	3.2	53
377	Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 3933-3938.	3.3	641
378	Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 6302-6309.	3.2	1,975

#	ARTICLE	IF	CITATIONS
379	CCL2 Protects Prostate Cancer PC3 Cells from Autophagic Death via Phosphatidylinositol 3-Kinase/AKT-dependent Survivin Up-regulation. <i>Journal of Biological Chemistry</i> , 2008, 283, 25057-25073.	1.6	156
380	The Role of CXCR7/RDC1 as a Chemokine Receptor for CXCL12/SDF-1 in Prostate Cancer. <i>Journal of Biological Chemistry</i> , 2008, 283, 4283-4294.	1.6	412
381	CCL2, survivin and autophagy: New links with implications in human cancer. <i>Autophagy</i> , 2008, 4, 969-971.	4.3	47
382	Solid Tumors Target the HSC Niche to Establish Metastatic Footholds in the Marrow. <i>Blood</i> , 2008, 112, 552-552.	0.6	0
383	Living With Prostate Cancer: Patients' and Spouses' Psychosocial Status and Quality of Life. <i>Journal of Clinical Oncology</i> , 2007, 25, 4171-4177.	0.8	188
384	A Polycomb Repression Signature in Metastatic Prostate Cancer Predicts Cancer Outcome. <i>Cancer Research</i> , 2007, 67, 10657-10663.	0.4	308
385	A Glycolytic Mechanism Regulating an Angiogenic Switch in Prostate Cancer. <i>Cancer Research</i> , 2007, 67, 149-159.	0.4	140
386	Targeting CCL2 with Systemic Delivery of Neutralizing Antibodies Induces Prostate Cancer Tumor Regression <i>In vivo</i> . <i>Cancer Research</i> , 2007, 67, 9417-9424.	0.4	305
387	An Imaging Biomarker of Early Treatment Response in Prostate Cancer that Has Metastasized to the Bone. <i>Cancer Research</i> , 2007, 67, 3524-3528.	0.4	70
388	Integrative Analysis of Genomic Aberrations Associated with Prostate Cancer Progression. <i>Cancer Research</i> , 2007, 67, 8229-8239.	0.4	103
389	A Hierarchical Network of Transcription Factors Governs Androgen Receptor-Dependent Prostate Cancer Growth. <i>Molecular Cell</i> , 2007, 27, 380-392.	4.5	598
390	In Vivo Evaluation of AT-101 (R-( $\alpha$ )-Gossypol Acetic Acid) in Androgen-Independent Growth of VCaP Prostate Cancer Cells in Combination with Surgical Castration. <i>Neoplasia</i> , 2007, 9, 1030-1037.	2.3	52
391	A Feasibility Study Evaluating the Functional Diffusion Map as a Predictive Imaging Biomarker for Detection of Treatment Response in a Patient with Metastatic Prostate Cancer to the Bone. <i>Neoplasia</i> , 2007, 9, 1003-1011.	2.3	101
392	CCL2 as an Important Mediator of Prostate Cancer Growth In Vivo through the Regulation of Macrophage Infiltration. <i>Neoplasia</i> , 2007, 9, 556-562.	2.3	203
393	Galectin-3 as a Potential Therapeutic Target in Tumors Arising from Malignant Endothelia. <i>Neoplasia</i> , 2007, 9, 662-670.	2.3	89
394	The Lethal Phenotype of Cancer: The Molecular Basis of Death Due to Malignancy. <i>Ca-A Cancer Journal for Clinicians</i> , 2007, 57, 225-241.	157.7	145
395	Phase II Evaluation of Oral Estramustine, Oral Etoposide, and Intravenous Paclitaxel in Patients with Hormone-Sensitive Prostate Adenocarcinoma. <i>Clinical Genitourinary Cancer</i> , 2007, 5, 318-322.	0.9	8
396	PAR1-mediated RhoA activation facilitates CCL2-induced chemotaxis in PC-3 cells. <i>Journal of Cellular Biochemistry</i> , 2007, 101, 1292-1300.	1.2	33

#	ARTICLE	IF	CITATIONS
397	Randomized clinical trial of a family intervention for prostate cancer patients and their spouses. <i>Cancer</i> , 2007, 110, 2809-2818.	2.0	283
398	Expression and activation of $\alpha_5\beta_1$ integrins by SDF-1/CXCL12 increases the aggressiveness of prostate cancer cells. <i>Prostate</i> , 2007, 67, 61-73.	1.2	167
399	Integrative molecular concept modeling of prostate cancer progression. <i>Nature Genetics</i> , 2007, 39, 41-51.	9.4	837
400	Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. <i>Modern Pathology</i> , 2007, 20, 538-544.	2.9	281
401	Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. <i>Nature</i> , 2007, 448, 595-599.	13.7	743
402	Bone metastasis and cancer. <i>Cancer and Metastasis Reviews</i> , 2007, 25, 505-505.	2.7	0
403	The evolving biology and treatment of prostate cancer. <i>Journal of Clinical Investigation</i> , 2007, 117, 2351-2361.	3.9	119
404	Simulating the Hallmarks of Cancer. <i>Artificial Life</i> , 2006, 12, 617-634.	1.0	83
405	Evolution of cooperation among tumor cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 13474-13479.	3.3	385
406	CCL2 is a Potent Regulator of Prostate Cancer Cell Migration and Proliferation. <i>Neoplasia</i> , 2006, 8, 578-586.	2.3	219
407	Inhibition of Decay-Accelerating Factor (CD55) Attenuates Prostate Cancer Growth and Survival In Vivo. <i>Neoplasia</i> , 2006, 8, 69-78.	2.3	60
408	Development of the VCaP androgen-independent model of prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2006, 24, 161-168.	0.8	42
409	GREB1 is a novel androgen-regulated gene required for prostate cancer growth. <i>Prostate</i> , 2006, 66, 886-894.	1.2	65
410	Phase II Trial of Copper Depletion with Tetrathiomolybdate as an Antiangiogenesis Strategy in Patients with Hormone-Refractory Prostate Cancer. <i>Oncology</i> , 2006, 71, 168-175.	0.9	68
411	Phase II Evaluations of Cilengitide in Asymptomatic Patients with Androgen-Independent Prostate Cancer: Scientific Rationale and Study Design. <i>Clinical Genitourinary Cancer</i> , 2006, 4, 299-302.	0.9	73
412	Phase II trial of oral uracil/tegafur plus leucovorin in patients with hormone-refractory prostate carcinoma. <i>Cancer</i> , 2006, 106, 1715-1721.	2.0	10
413	Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate. <i>Cancer</i> , 2006, 106, 2617-2623.	2.0	4
414	Mechanisms Underlying the Development of Androgen-Independent Prostate Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 1665-1671.	3.2	387



#	ARTICLE	IF	CITATIONS
415	Modeling Somatic Evolution in Tumorigenesis. <i>PLoS Computational Biology</i> , 2006, 2, e108.	1.5	84
416	TMPRSS2:ERG Fusion-Associated Deletions Provide Insight into the Heterogeneity of Prostate Cancer. <i>Cancer Research</i> , 2006, 66, 8337-8341.	0.4	475
417	Modeling Cancer as A Complex Adaptive System: Genetic Instability and Evolution. , 2006, , 537-556.		0
418	Prostate cancer presenting as visual changes. <i>Anticancer Research</i> , 2006, 26, 755-8.	0.5	2
419	Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer. <i>Science</i> , 2005, 310, 644-648.	6.0	3,541
420	Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. <i>Cancer Cell</i> , 2005, 8, 393-406.	7.7	731
421	Advances in Prostate Cancer Chemotherapy: A New Era Begins. <i>Ca-A Cancer Journal for Clinicians</i> , 2005, 55, 300-318.	157.7	146
422	A paradigm for the treatment of prostate cancer bone metastases based on an understanding of tumor cell-microenvironment interactions. <i>Journal of Cellular Biochemistry</i> , 2005, 96, 439-446.	1.2	43
423	PAR1-mediated NF $\kappa$ B activation promotes survival of prostate cancer cells through a Bcl-xL-dependent mechanism. <i>Journal of Cellular Biochemistry</i> , 2005, 96, 641-652.	1.2	78
424	Amplification and overexpression of prosaposin in prostate cancer. <i>Genes Chromosomes and Cancer</i> , 2005, 44, 351-364.	1.5	46
425	Pathogenesis and Treatment of Prostate Cancer Bone Metastases: Targeting the Lethal Phenotype. <i>Journal of Clinical Oncology</i> , 2005, 23, 8232-8241.	0.8	135
426	Bone Turnover Mediates Preferential Localization of Prostate Cancer in the Skeleton. <i>Endocrinology</i> , 2005, 146, 1727-1736.	1.4	174
427	Identification of Leukocyte E-Selectin Ligands, P-Selectin Glycoprotein Ligand-1 and E-Selectin Ligand-1, on Human Metastatic Prostate Tumor Cells. <i>Cancer Research</i> , 2005, 65, 5750-5760.	0.4	112
428	Drug Insight: use of docetaxel in prostate and urothelial cancers. <i>Nature Reviews Urology</i> , 2005, 2, 92-100.	1.4	48
429	Letter to the Editor: Androgens and Prostate Cancer: Are the Descriptors Valid?. <i>Cancer Biology and Therapy</i> , 2005, 4, 4-5.	1.5	44
430	Autoantibody Signatures in Prostate Cancer. <i>New England Journal of Medicine</i> , 2005, 353, 1224-1235.	13.9	581
431	Preliminary study of immunomagnetic quantification of circulating tumor cells in patients with advanced disease. <i>Urology</i> , 2005, 65, 616-621.	0.5	38
432	Osteonecrosis of jaw in patient with hormone-refractory prostate cancer treated with zoledronic acid. <i>Urology</i> , 2005, 66, 658.e1-658.e3.	0.5	37

#	ARTICLE	IF	CITATIONS
433	Analysis of membrane-bound complement regulatory proteins in prostate cancer. <i>Urology</i> , 2005, 66, 1321-1326.	0.5	34
434	Stromal-epithelial interactions influence prostate cancer cell invasion by altering the balance of metallopeptidase expression. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2005, 23, 73-74.	0.8	0
435	Enhanced invasion of hormone refractory prostate cancer cells through hepatocyte growth factor (HGF) induction of urokinase-type plasminogen activator (u-PA). <i>Urologic Oncology: Seminars and Original Investigations</i> , 2005, 23, 74.	0.8	0
436	Involvement of MAPK pathway in hypoxia-induced up-regulation of urokinase plasminogen activator receptor in a human prostatic cancer cell line, PC3MLN4. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2005, 23, 75.	0.8	0
437	Secreted transforming growth factor beta2 activates NF-kappaB, blocks apoptosis, and is essential for the survival of some tumor cells. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2005, 23, 75.	0.8	0
438	Expression of vascular endothelial growth factor receptor-3 by lymphatic endothelial cells is associated with lymph node metastasis in prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2005, 23, 76.	0.8	0
439	The "Emigration, Migration, and Immigration" of Prostate Cancer. <i>Clinical Prostate Cancer</i> , 2005, 4, 24-30.	2.1	57
440	Radiation Therapy Oncology Group 0521: A Phase III Randomized Trial of Androgen Suppression and Radiation Therapy Versus Androgen Suppression and Radiation Therapy Followed by Docetaxel/Prednisone for Localized, High-Risk Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2005, 4, 212-214.	0.9	17
441	Mechanical Entrapment Is Insufficient and Intercellular Adhesion Is Essential for Metastatic Cell Arrest in Distant Organs. <i>Neoplasia</i> , 2005, 7, 522-527.	2.3	160
442	Global Gene Expression Profiling of Circulating Tumor Cells. <i>Cancer Research</i> , 2005, 65, 4993-4997.	0.4	328
443	Proptosis and decreased vision secondary to prostate cancer orbital wall metastasis. <i>Anticancer Research</i> , 2005, 25, 3521-2.	0.5	11
444	Eligibility and Outcomes Reporting Guidelines for Clinical Trials for Patients in the State of a Rising Prostate-Specific Antigen: Recommendations From the Prostate-Specific Antigen Working Group. <i>Journal of Clinical Oncology</i> , 2004, 22, 537-556.	0.8	189
445	Overexpression, Amplification, and Androgen Regulation of TPD52 in Prostate Cancer. <i>Cancer Research</i> , 2004, 64, 3814-3822.	0.4	145
446	Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases. <i>Cancer Research</i> , 2004, 64, 9209-9216.	0.4	816
447	Evidence of porcine and human endothelium activation by cancer-associated carbohydrates expressed on glycoproteins and tumour cells. <i>Journal of Physiology</i> , 2004, 554, 89-99.	1.3	42
448	Skeletal Localization and Neutralization of the SDF-1(CXCL12)/CXCR4 Axis Blocks Prostate Cancer Metastasis and Growth in Osseous Sites In Vivo. <i>Journal of Bone and Mineral Research</i> , 2004, 20, 318-329.	3.1	345
449	In vivo real-time imaging of TGF- $\beta$ -induced transcriptional activation of the RANK ligand gene promoter in intraosseous prostate cancer. <i>Prostate</i> , 2004, 59, 360-369.	1.2	42
450	Apoptosis of circulating tumor cells in prostate cancer patients. <i>Cytometry</i> , 2004, 62A, 46-53.	1.8	131

#	ARTICLE	IF	CITATIONS
451	Expression mapping at 12p12-13 in advanced prostate carcinoma. <i>International Journal of Cancer</i> , 2004, 109, 668-672.	2.3	21
452	Cellular interactions in the tropism of prostate cancer to bone. <i>International Journal of Cancer</i> , 2004, 110, 497-503.	2.3	60
453	Dynamic process of prostate cancer metastasis to bone. <i>Journal of Cellular Biochemistry</i> , 2004, 91, 706-717.	1.2	91
454	Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. <i>Human Molecular Genetics</i> , 2004, 13, 1303-1313.	1.4	171
455	Detection and Isolation of Circulating Tumor Cells in Urologic Cancers: A Review. <i>Neoplasia</i> , 2004, 6, 302-309.	2.3	53
456	Expression of the Platelet-Derived Growth Factor Receptor in Prostate Cancer and Treatment Implications with Tyrosine Kinase Inhibitors. <i>Neoplasia</i> , 2004, 6, 503-512.	2.3	49
457	Expression and regulation of MIM (Missing In Metastasis), a novel putative metastasis suppressor gene, and MIM-B, in bladder cancer cell lines. <i>Cancer Letters</i> , 2004, 215, 209-220.	3.2	54
458	Testicular cancer. <i>Current Opinion in Oncology</i> , 2004, 16, 253-256.	1.1	9
459	Cancer Cells Homing to Bone: The Significance of Chemotaxis and Cell Adhesion. <i>Cancer Treatment and Research</i> , 2004, 118, 291-309.	0.2	15
460	Continuous real time ex vivo epifluorescent video microscopy for the study of metastatic cancer cell interactions with microvascular endothelium. <i>Clinical and Experimental Metastasis</i> , 2003, 20, 451-458.	1.7	27
461	Stromal factors involved in prostate carcinoma metastasis to bone. <i>Cancer</i> , 2003, 97, 739-747.	2.0	168
462	Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma. <i>Cancer</i> , 2003, 98, 269-276.	2.0	34
463	Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen-independent prostate carcinoma. <i>Cancer</i> , 2003, 98, 1603-1610.	2.0	35
464	Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. <i>Journal of Cellular Biochemistry</i> , 2003, 89, 462-473.	1.2	405
465	Radiation Therapy Oncology Group P-0014: a phase 3 randomized study of patients with high-risk hormone-naïve prostate cancer: androgen blockade with 4 cycles of immediate chemotherapy versus androgen blockade with delayed chemotherapy. <i>Urology</i> , 2003, 62, 95-101.	0.5	6
466	Prostate-specific antigen doubling time and survival in patients with advanced metastatic prostate cancer. <i>Urology</i> , 2003, 62, 128-133.	0.5	35
467	The truth is out there: an overall perspective on androgen deprivation. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2003, 21, 272-281.	0.8	12
468	Germ cell tumors: review of selected studies from 2002. <i>Current Opinion in Oncology</i> , 2003, 15, 234-238.	1.1	7

#	ARTICLE	IF	CITATIONS
469	Androgen-independent Prostate Cancer: The Evolving Role of Chemotherapy. , 2003, , 423-433.		2
470	Rationale for the Radiation Therapy Oncology Group Study RTOG P-0014. Reviews in Urology, 2003, 5 Suppl 2, S28-34.	0.9	0
471	Rationale for the Radiation Therapy Oncology Group Study RTOG P-0014. Reviews in Urology, 2003, 5 Suppl 3, S45-51.	0.9	0
472	Intravascular metastatic cancer cell homotypic aggregation at the sites of primary attachment to the endothelium. Cancer Research, 2003, 63, 3805-11.	0.4	209
473	In vivo visualization of metastatic prostate cancer and quantitation of disease progression in immunocompromised mice. Cancer Biology and Therapy, 2003, 2, 656-60.	1.5	28
474	The role of an 80 kDa fragment of E-cadherin in the metastatic progression of prostate cancer. Clinical Cancer Research, 2003, 9, 6447-52.	3.2	69
475	Î±-Methylacyl Coenzyme A Racemase as a Tissue Biomarker for Prostate Cancer. JAMA - Journal of the American Medical Association, 2002, 287, 1662.	3.8	565
476	Tissue Microarray Sampling Strategy for Prostate Cancer Biomarker Analysis. American Journal of Surgical Pathology, 2002, 26, 312-319.	2.1	294
477	Testicular cancer. Current Opinion in Oncology, 2002, 14, 260-264.	1.1	6
478	Antimetastatic Drugs in Prostate Cancer. Clinical Prostate Cancer, 2002, 1, 14-19.	2.1	7
479	MIM, a Potential Metastasis Suppressor Gene in Bladder Cancer. Neoplasia, 2002, 4, 291-294.	2.3	148
480	Suppression of Tumor Recurrence and Metastasis by a Combination of the PHSCN Sequence and the Antiangiogenic Compound Tetrathiomolybdate in Prostate Carcinoma. Neoplasia, 2002, 4, 373-379.	2.3	63
481	Mind-body effect: insulinlike growth factor-1; clinical depression; and breast, prostate, and other cancer riskâ€”an unmeasured and masked mediator of potential significance?. Urology, 2002, 59, 4-8.	0.5	8
482	A functional thrombin receptor (PAR1) is expressed on bone-derived prostate cancer cell lines. Urology, 2002, 60, 760-765.	0.5	90
483	The Role of Î±vÎ²3 in Prostate Cancer Progression. Neoplasia, 2002, 4, 191-194.	2.3	188
484	Prostate carcinoma skeletal metastases: Cross-talk between tumor and bone. , 2002, , 197-213.		0
485	The Current State of Hormonal Therapy for Prostate Cancer. Ca-A Cancer Journal for Clinicians, 2002, 52, 154-179.	157.7	323
486	APC/CTNNB1 (Î²-catenin) pathway alterations in human prostate cancers. Genes Chromosomes and Cancer, 2002, 34, 9-16.	1.5	152

#	ARTICLE	IF	CITATIONS
487	The polycomb group protein EZH2 is involved in progression of prostate cancer. <i>Nature</i> , 2002, 419, 624-629.	13.7	2,411
488	The regulation of prostate cancer cell adhesion to human bone marrow endothelial cell monolayers by androgen dihydrotestosterone and cytokines. <i>Clinical and Experimental Metastasis</i> , 2002, 19, 25-33.	1.7	29
489	The role of alpha(v)beta(3) in prostate cancer progression. <i>Neoplasia</i> , 2002, 4, 191-4.	2.3	115
490	Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. <i>Cancer Research</i> , 2002, 62, 1832-7.	0.4	768
491	E-cadherin expression in prostate cancer: A broad survey using high-density tissue microarray technology. <i>Human Pathology</i> , 2001, 32, 690-697.	1.1	159
492	Chemotherapy in patients with prostate specific antigen-only disease after primary therapy for prostate carcinoma. <i>Cancer</i> , 2001, 91, 2175-2180.	2.0	7
493	A phase II trial of estramustine and etoposide in hormone refractory prostate cancer: A Southwest Oncology Group trial (SWOG 9407). <i>Prostate</i> , 2001, 46, 257-261.	1.2	29
494	Prostate carcinoma skeletal metastases: cross-talk between tumor and bone. <i>Cancer and Metastasis Reviews</i> , 2001, 20, 333-349.	2.7	179
495	Delineation of prognostic biomarkers in prostate cancer. <i>Nature</i> , 2001, 412, 822-826.	13.7	1,551
496	Decreased galectin-3 expression in prostate cancer. <i>Prostate</i> , 2000, 44, 118-123.	1.2	98
497	Phenotypic characterization of immortalized normal and primary tumor-derived human prostate epithelial cell cultures. <i>Prostate</i> , 2000, 44, 164-171.	1.2	35
498	Treatment of androgen-independent prostate cancer using antimicrotubule agents docetaxel and estramustine in combination: an experimental study. <i>Prostate</i> , 2000, 44, 275-278.	1.2	32
499	Evidence for lectin signaling to the nuclear matrix: Cellular interpretation of the glycodecode. <i>Journal of Cellular Biochemistry</i> , 2000, 79, 123-129.	1.2	8
500	Genetic Characterization of Immortalized Human Prostate Epithelial Cell Cultures. <i>Cancer Genetics and Cytogenetics</i> , 2000, 120, 50-57.	1.0	26
501	Recent advances in chemotherapy for advanced prostate cancer. <i>Current Urology Reports</i> , 2000, 1, 48-56.	1.0	4
502	Modified Differential Display Technique that Eliminates Radioactivity and Decreases Screening Time. <i>BioTechniques</i> , 2000, 28, 272-277.	0.8	5
503	Expression of Nuclear Antigen Ki-67 in Prostate Cancer Needle Biopsy and Radical Prostatectomy Specimens. <i>Journal of the National Cancer Institute</i> , 2000, 92, 1941-1942.	3.0	35
504	Etoposide in prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2000, 1, 271-275.	0.9	13

#	ARTICLE	IF	CITATIONS
505	Galectin-3 Induces Endothelial Cell Morphogenesis and Angiogenesis. American Journal of Pathology, 2000, 156, 899-909.	1.9	402
506	Hormonal Manipulation of Prostate Cancer. , 2000, , 293-311.		0
507	New Paradigms in the Management of Hormone Refractory Disease. , 2000, , 289-303.		0
508	Phase II Trial of Oral Estramustine, Oral Etoposide, and Intravenous Paclitaxel in Hormone-Refractory Prostate Cancer. Journal of Clinical Oncology, 1999, 17, 1664-1664.	0.8	158
509	A new concept in cancer care: The supportive care program. American Journal of Hospice and Palliative Medicine, 1999, 16, 713-722.	0.8	19
510	Skeletal metastasis of prostate adenocarcinoma in rats: Morphometric analysis and role of parathyroid hormone-related protein. , 1999, 39, 187-197.		51
511	Oral Chemotherapy in the Treatment of Hormone-Refractory Prostate Cancer. Drugs, 1999, 58, 127-131.	4.9	4
512	Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology, 1999, 53, 260-266.	0.5	199
513	Discussion. Urology, 1999, 53, 1073-1076.	0.5	12
514	Use of PC-SPEs, a commercially available supplement for prostate cancer, in a patient with hormone-naive disease. Urology, 1999, 54, 319-323.	0.5	45
515	Signaling network of paclitaxel-induced apoptosis in the LNCaP prostate cancer cell line. Urology, 1999, 54, 746-752.	0.5	13
516	Early castration reduces prostatic carcinogenesis in transgenic mice. Urology, 1999, 54, 1112-1119.	0.5	61
517	RATIONAL USE OF CHEMOTHERAPY. Urologic Clinics of North America, 1999, 26, 275-279.	0.8	0
518	Current Chemotherapy Regimens. Urologic Clinics of North America, 1999, 26, 419-421.	0.8	0
519	ORAL CHEMOTHERAPY FOR HORMONE REFRACTORY PROSTATE CANCER. Urologic Clinics of North America, 1999, 26, 333-340.	0.8	6
520	Skeletal metastasis of prostate adenocarcinoma in rats: Morphometric analysis and role of parathyroid hormone-related protein. , 1999, 39, 187.		1
521	Hormone resistance in prostate cancer. Cancer and Metastasis Reviews, 1998, 17, 373-381.	2.7	71
522	LONGITUDINAL COHORT ANALYSIS OF LETHAL PROSTATE CANCER PROGRESSION IN TRANSGENIC MICE. Journal of Urology, 1998, 160, 1500-1505.	0.2	49

#	ARTICLE	IF	CITATIONS
523	A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer. <i>Urology</i> , 1998, 52, 257-260.	0.5	164
524	Preferential Adhesion of Prostate Cancer Cells to a Human Bone Marrow Endothelial Cell Line. <i>Journal of the National Cancer Institute</i> , 1998, 90, 118-123.	3.0	203
525	Explaining Aberrations of Cell Structure and Cell Signaling in Cancer Using Complex Adaptive Systems. <i>Advances in Molecular and Cell Biology</i> , 1997, 24, 207-247.	0.1	4
526	A phase ii trial of oral estramustine and oral etoposide in hormone refractory prostate cancer. <i>Urology</i> , 1997, 50, 401-407.	0.5	92
527	Measuring quality of life in men with prostate cancer using the Functional Assessment of Cancer Therapy-prostate instrument. <i>Urology</i> , 1997, 50, 920-928.	0.5	595
528	THE USE OF PROSTATE-SPECIFIC ANTIGEN AS A SURROGATE END POINT IN THE TREATMENT OF PATIENTS WITH HORMONE REFRACTORY PROSTATE CANCER. <i>Urologic Clinics of North America</i> , 1997, 24, 433-437.	0.8	11
529	Phase II Chemoprevention Trial of Oral Fenretinide in Patients at Risk for Adenocarcinoma of the Prostate. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1997, 20, 36-39.	0.6	63
530	Effect of estramustine, etoposide, and taxol on prostate cancer cell growth in vitro and in vivo. <i>Urology</i> , 1996, 48, 164-170.	0.5	38
531	Inhibition of prostate cancer growth by 9-aminocamptothecin and estramustine. <i>Urology</i> , 1996, 48, 508-511.	0.5	7
532	Epidemiology of prostate cancer: molecular and environmental clues. <i>Urology</i> , 1996, 48, 676-683.	0.5	40
533	Hormonal and Chemotherapeutic Systemic Therapy for Metastatic Prostate Cancer. <i>Cancer Control</i> , 1996, 3, 493-500.	0.7	3
534	Effect of organ site on nuclear matrix protein composition. , 1996, 62, 132-141.		7
535	Role of the nuclear matrix in breast cancer. <i>Cancer Treatment and Research</i> , 1996, 83, 127-140.	0.2	1
536	A Phase II Evaluation of Oral Tamoxifen and Intermittent Intravenous Vinblastine in Hormone-Refractory Adenocarcinoma of the Prostate. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1996, 19, 500-503.	0.6	7
537	Inhibition of prostate cancer growth by estramustine and etoposide. <i>Cancer</i> , 1995, 75, 1920-1926.	2.0	8
538	Loss of cell-contact regulation and altered responses to autocrine motility factor correlate with increased malignancy in prostate cancer cells. <i>International Journal of Cancer</i> , 1995, 63, 100-105.	2.3	32
539	Electroretinographic findings in subjects after administration of fenretinide. <i>Documenta Ophthalmologica</i> , 1995, 91, 299-309.	1.0	2
540	Inhibition of prostate cancer growth by vinblastine and tamoxifen. <i>Prostate</i> , 1995, 26, 270-274.	1.2	13

#	ARTICLE	IF	CITATIONS
541	Inhibition of prostate cancer growth by estramustine and colchicine. <i>Prostate</i> , 1995, 26, 310-315.	1.2	26
542	Galectin-3 Is a Nuclear Matrix Protein Which Binds RNA. <i>Biochemical and Biophysical Research Communications</i> , 1995, 217, 292-303.	1.0	77
543	Effect of age and race on the survival of men with prostate cancer in the Metropolitan Detroit tricounty area, 1973 to 1987. <i>Urology</i> , 1995, 45, 93-101.	0.5	122
544	Oral etoposide in the treatment of hormone-refractory prostate cancer. <i>Cancer</i> , 1994, 74, 100-103.	2.0	45
545	Coupling of cell structure to cell metabolism and function. <i>Journal of Cellular Biochemistry</i> , 1994, 55, 16-21.	1.2	19
546	Alterations in cellular gene expression without changes in nuclear matrix protein content. <i>Journal of Cellular Biochemistry</i> , 1994, 56, 502-509.	1.2	1
547	Review of the role of androgenic hormones in the epidemiology of benign prostatic hyperplasia and prostate cancer. <i>Urology</i> , 1994, 43, 892-899.	0.5	92
548	An unstable nuclear matrix may contribute to genetic instability. <i>Medical Hypotheses</i> , 1994, 42, 45-52.	0.8	21
549	Effect of prostatic inhibin peptide (PIP) on prostate cancer cell growth in vitro and in vivo. <i>Prostate</i> , 1993, 22, 225-233.	1.2	40
550	A common set of nuclear matrix proteins in prostate cancer cells. <i>Prostate</i> , 1993, 23, 61-67.	1.2	19
551	A comparative study on expression of prostatic inhibin peptide, prostate acid phosphatase and prostate specific antigen in androgen independent human and rat prostate carcinoma cell lines. <i>Cancer Letters</i> , 1993, 70, 159-166.	3.2	32
552	Risk Factors for Prostate Cancer. <i>Annals of Internal Medicine</i> , 1993, 118, 793.	2.0	356
553	The Tissue Matrix and The Regulation of Gene Expression in Cancer Cells. <i>Advances in Molecular and Cell Biology</i> , 1993, 7, 131-156.	0.1	6
554	Inhibition of Prostate Cancer Growth by Estramustine and Etoposide: Evidence For Interaction at the Nuclear Matrix. <i>Journal of Urology</i> , 1993, 149, 1622-1625.	0.2	98
555	Characterization of nuclear morphology and nuclear matrices in ageing human fibroblasts. <i>Mechanisms of Ageing and Development</i> , 1992, 62, 13-24.	2.2	18
556	Effects of extracellular matrix components and dihydrotestosterone on the structure and function of human prostate cancer cells. <i>Prostate</i> , 1992, 20, 29-41.	1.2	21
557	Effect of pentosan, a novel cancer chemotherapeutic agent, on prostate cancer cell growth and motility. <i>Prostate</i> , 1992, 20, 233-241.	1.2	23
558	The effect of age on the response of the detrusor to intracellular mechanical stimulus: DNA replication and the cell actin matrix. <i>Journal of Cellular Biochemistry</i> , 1992, 48, 373-384.	1.2	13



#	ARTICLE	IF	CITATIONS
559	Nuclear-Cytoskeletal interactions: Evidence for physical connections between the nucleus and cell periphery and their alteration by transformation. <i>Journal of Cellular Biochemistry</i> , 1992, 49, 357-365.	1.2	90
560	The effect of extracellular matrix interactions on morphologic transformation invitro. <i>Biochemical and Biophysical Research Communications</i> , 1991, 179, 333-339.	1.0	25
561	Modifications of the intermediate filament and nuclear matrix networks by the extracellular matrix. <i>Biochemical and Biophysical Research Communications</i> , 1991, 179, 340-344.	1.0	23
562	Cellular harmonic information transfer through a tissue tensegrity-matrix system. <i>Medical Hypotheses</i> , 1991, 34, 88-95.	0.8	69
563	The Effects of Basic Fibroblast Growth Factor and suramin on Cell Motility and Growth of Rat Prostate Cancer Cells. <i>Journal of Urology</i> , 1991, 145, 199-202.	0.2	65
564	Nuclear structure and the three-dimensional organization of DNA. <i>Journal of Cellular Biochemistry</i> , 1991, 47, 289-299.	1.2	151
565	Correlation of nuclear morphometry with progression of breast cancer. <i>Cancer</i> , 1991, 68, 2012-2016.	2.0	113
566	The Tissue Matrix: Cell Dynamics and Hormone Action*. <i>Endocrine Reviews</i> , 1990, 11, 399-417.	8.9	129
567	Characterization of the subtypes of cell motility in ageing human skin fibroblasts. <i>Mechanisms of Ageing and Development</i> , 1990, 56, 99-105.	2.2	49
568	A structural analysis of the role of the nuclear matrix and DNA loops in the organization of the nucleus and chromosome. <i>Journal of Cell Science</i> , 1984, 1984, 123-135.	1.2	184
569	Prostate Cancer Metastasis: Thoughts on Biology and Therapeutics. , 0, , 456-464.		0
570	The marrow niche controls the cancer stem cell phenotype of disseminated prostate cancer. <i>Oncotarget</i> , 0, 7, 41217-41232.	0.8	57